Cubist Pharmaceuticals Inc. (CBST) Stock Analysis
DELISTED 2015
What happened to Cubist Pharmaceuticals Inc. (CBST) stock?
Cubist Pharmaceuticals Inc. (CBST) no longer trades on public markets. It was delisted in February 2015. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cubist Pharmaceuticals Inc. (CBST) trades at $101.94. Cubist Pharmaceuticals LLC focuses on the research, development, and commercialization of pharmaceutical products. The company addresses unmet medical needs within the acute care environment. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for CBST: CBST does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBST against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
CBST: this read rests on a single discipline (Legends Council) — the other council disciplines have no scored data yet.
How is this calculated? →Cubist Pharmaceuticals Inc. (CBST) Healthcare & Pipeline Overview
Cubist Pharmaceuticals LLC operates as a pharmaceutical company focused on addressing unmet medical needs in the acute care environment. With a portfolio centered on innovative therapies, Cubist aims to improve patient outcomes and combat serious infections, positioning itself within the competitive biotechnology landscape.
What Is the Investment Thesis for CBST?
Cubist Pharmaceuticals LLC presents a focused investment opportunity within the biotechnology sector, driven by its specialization in anti-infective therapies. The company's value is rooted in its ability to develop and commercialize innovative solutions for unmet medical needs in acute care. Cubist's growth potential is tied to the success of its pipeline and its ability to expand its market presence. However, potential investors may want to evaluate the risks associated with pharmaceutical development, including regulatory hurdles and competition from established players. As of 2026, the company's financial performance and strategic initiatives will be key indicators of its long-term value.
Based on FMP financials and quantitative analysis
CBST Key Highlights
Cubist Pharmaceuticals focuses on unmet medical needs in the acute care environment.
- The company specializes in the research, development, and commercialization of pharmaceutical products.
- Cubist's portfolio targets serious and life-threatening infections.
- The company operates primarily in the United States.
- Cubist has a beta of 0.70, indicating lower volatility compared to the market.
Who Are CBST's Competitors?
CBST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBST's Key Strengths?
Focus on unmet medical needs
- Expertise in anti-infective therapies
- Strong relationships with hospitals
- Innovative pharmaceutical products
What Are CBST's Weaknesses?
Reliance on a limited number of products
- Exposure to regulatory risks
- Dependence on patent protection
- Competition from larger pharmaceutical companies
What Could Drive CBST Stock Higher?
Clinical trial results for novel anti-infective therapies.
- Regulatory approvals for new drug applications.
- Expansion into new geographic markets.
- Strategic partnerships with academic institutions.
What Are the Key Risks for CBST?
Insider selling — insiders were net sellers of roughly $4.7M recently.
- Patent expirations leading to generic competition.
- Regulatory setbacks delaying or preventing drug approvals.
- Emergence of new drug-resistant bacteria.
- Competition from larger pharmaceutical companies.
- Dependence on key personnel.
What Are the Growth Opportunities for CBST?
- Expansion into New Therapeutic Areas: Cubist Pharmaceuticals has the opportunity to leverage its expertise in anti-infectives to expand into related therapeutic areas, such as immunology or virology. By diversifying its pipeline, Cubist can reduce its reliance on a single market and capitalize on emerging opportunities in adjacent fields. The market for immunomodulatory therapies is projected to reach $150 billion by 2028, offering a significant growth avenue for Cubist. This expansion would require strategic acquisitions or partnerships to acquire new technologies and expertise, with potential launches starting in 2027.
- Geographic Expansion: Cubist Pharmaceuticals can pursue growth by expanding its geographic presence beyond the United States. Emerging markets, such as China and India, represent significant opportunities for anti-infective therapies due to the high prevalence of infectious diseases and increasing healthcare spending. The pharmaceutical market in China is expected to reach $400 billion by 2030, providing a substantial growth opportunity for Cubist. This expansion would require establishing local partnerships and navigating regulatory hurdles, with potential market entry starting in 2028.
- Strategic Acquisitions: Cubist Pharmaceuticals can drive growth through strategic acquisitions of smaller biotech companies with promising drug candidates or innovative technologies. By acquiring complementary assets, Cubist can strengthen its pipeline, expand its market share, and accelerate its growth trajectory. The market for biotech acquisitions is expected to remain active, with numerous opportunities for Cubist to acquire valuable assets. These acquisitions would require careful due diligence and integration planning, with potential deals closing in 2026 and beyond.
- Development of Novel Drug Delivery Systems: Cubist Pharmaceuticals can enhance the value of its existing products by developing novel drug delivery systems that improve efficacy, reduce side effects, and enhance patient compliance. These delivery systems could include sustained-release formulations, targeted drug delivery technologies, or novel routes of administration. The market for drug delivery systems is projected to reach $100 billion by 2029, offering a significant opportunity for Cubist to differentiate its products and gain a competitive advantage. This development would require investment in research and development, with potential product launches starting in 2027.
- Collaboration with Academic Institutions: Cubist Pharmaceuticals can foster innovation and accelerate its research and development efforts by collaborating with leading academic institutions and research centers. These collaborations can provide access to cutting-edge technologies, novel drug targets, and expert scientific knowledge. The market for academic collaborations is expected to grow, with increasing demand for industry-academia partnerships to drive innovation in drug discovery and development. These collaborations would require establishing strategic partnerships and funding research projects, with potential breakthroughs starting in 2028.
What Are CBST's Competitive Advantages?
- Patented pharmaceutical products
- Specialized expertise in anti-infective therapies
- Established relationships with hospitals and healthcare providers
- Strong brand reputation in the acute care market
What Does CBST Do?
Cubist Pharmaceuticals LLC is a pharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. Founded with a focus on addressing critical unmet needs in acute care settings, the company has established itself as a key player in the fight against serious and life-threatening infections. Cubist's core business revolves around researching and developing innovative pharmaceutical products that target resistant bacteria and other challenging pathogens. The company's portfolio includes a range of anti-infective products designed to combat various types of infections, such as those affecting the skin, bloodstream, and respiratory system. Cubist's commitment to innovation extends beyond its existing product line, with ongoing research and development efforts focused on expanding its pipeline of novel therapies. These efforts aim to address emerging threats and improve treatment options for patients facing serious infections. Cubist operates primarily in the United States, with a focus on serving hospitals and other acute care facilities. The company's products are marketed and distributed through a combination of its own sales force and strategic partnerships.
What Products and Services Does CBST Offer?
- Researches and develops pharmaceutical products.
- Focuses on unmet medical needs in acute care.
- Commercializes pharmaceutical products.
- Targets serious and life-threatening infections.
- Develops anti-infective therapies.
- Addresses drug-resistant bacteria.
How Does CBST Make Money?
- Develops and patents novel pharmaceutical products.
- Conducts clinical trials to demonstrate safety and efficacy.
- Obtains regulatory approval from health authorities.
- Manufactures and markets its products to hospitals and healthcare providers.
What Industry Does CBST Operate In?
Cubist Pharmaceuticals LLC operates within the biotechnology industry, a sector characterized by rapid innovation and intense competition. The market for anti-infective therapies is driven by the increasing prevalence of drug-resistant bacteria and the need for new treatment options. Cubist competes with both large pharmaceutical companies and smaller biotech firms, all vying for market share in this critical area of healthcare. The biotechnology industry is subject to stringent regulatory oversight, with companies required to navigate complex approval processes and maintain high standards of quality and safety.
Who Are CBST's Key Customers?
- Hospitals
- Acute care facilities
- Healthcare providers
- Patients with serious infections
Company Profile
Cubist Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lexington, US. CBST has traded publicly since 1996.
Key Financial Metrics
Return on equity for Cubist Pharmaceuticals Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. CBST trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Insider Activity
The most recent 12 insider filings for Cubist Pharmaceuticals Inc. break down as 12 sales and 0 purchases. On net that is roughly 101K shares disposed (about $4.7M), a signal worth weighing alongside the fundamentals.
CBST Financials
Bull Case vs Bear Case
Bull Case
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in their pipeline.
- Analysts have noted an increase in demand for their products, particularly in the infectious disease sector, which could drive revenue.
- Recent partnerships and collaborations have bolstered market perception, indicating a robust strategy for expansion.
Bear Case
- Concerns over regulatory hurdles have surfaced, with some community members expressing skepticism about upcoming product approvals.
- Market sentiment remains cautious due to competitive pressures, with rivals launching similar therapies that could impact market share.
- Recent earnings calls showed mixed signals, leading to uncertainty among investors regarding future performance.
- Some analysts are highlighting potential supply chain issues that could affect production and delivery timelines.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CBST Latest News
No recent news available for CBST.
Common Questions About CBST (Healthcare)
What happened to Cubist Pharmaceuticals Inc. (CBST) stock?
Cubist Pharmaceuticals Inc. (CBST) no longer trades on public markets. It was delisted in February 2015. The figures below are historical and are not a current quote.
Can I still buy CBST shares?
No. CBST stopped trading on public markets in February 2015, so the shares are not available through a broker. Anything you see quoted for CBST elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before CBST stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Cubist Pharmaceuticals Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Cubist Pharmaceuticals Inc. do?
Cubist Pharmaceuticals LLC is a pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to address unmet medical needs in the acute care environment. The company specializes in anti-infective therapies, targeting serious and life-threatening infections caused by resistant bacteria and other challenging pathogens.
What are the main risks for CBST?
Cubist Pharmaceuticals LLC faces several risks inherent to the biotechnology industry. These include the potential for patent expirations, which could lead to generic competition and reduced revenue. Regulatory setbacks in drug development and approval processes pose another significant risk, potentially delaying or preventing the launch of new products.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and will provide further insights.